fell into the red zone at the end of the last week, falling into a negative trend and dropping by -24.30. is set at 0.18 The Price to Book ratio for the last quarter was 10.66, with the Price to Cash per share for the same quarter was set at 0.12. The Average True Range (ATR) for Sonnet BioTherapeutics Holdings Inc.
Here’s what leading stock market gurus have to say about Sonnet BioTherapeutics Holdings Inc.
If compared to the average trading volume of 5.19M shares, SONN reached to a volume of 13409384 in the most recent trading day, which is why market watchdogs consider the stock to be active. The stock has performed -37.89 percent around the most recent 30 days and changed -57.64 percent over the most recent 3-months. The stock has been moved at -75.49 percent over the last six months. The stocks have a year to date performance of -71.31 percent and weekly performance of -24.30 percent.
#Sonnet biotherapeutics full
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.Ĭlick here for full details and to join for freeīTIG is acting as the sole book-running manager in connection with the offering and Chardan is acting as lead manager. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential. He buys up valuable assets when they are very cheap. The offering is expected to close on or about August 24, 2021, subject to the satisfaction or waiver of customary closing conditions.ģ Tiny Stocks Primed to Explode The world's greatest investor - Warren Buffett - has a simple formula for making big money in the markets. The investor warrants have an exercise price of $0.85 per share. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one investor warrant to purchase one share of common stock at a combined offering price of $0.85, for total gross proceeds of approximately $30.0 million, before underwriting discounts and commissions and offering expenses payable by Sonnet. (NASDAQ:SONN) (“Sonnet” or the “Company”), a biopharmaceutical company developing innovative targeted biologic drugs, announced the pricing of an underwritten public offering of 35,294,117 shares of common stock or common stock equivalents (which includes pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 35,294,117 shares of common stock. The company report on Augthat Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering. The day’s price range saw the stock hit a low of $0.60, while the highest price level was $0.6525. closed the trading session at $0.64 on 08/24/21.
0 kommentar(er)
